The pathogenesis of CF-associated liver disease (CFLD) is incompletely understood, with onset and progression difficult to predict and monitor. Current measures of liver function, Cobimetinib datasheet combined with ultrasound and clinical examination are insensitive and non-specific for detection of early liver disease and assessment of progressive fibrosis severity. Although biopsy remains the gold standard for diagnosis of CFLD, it is invasive and can be confounded by the focal nature of disease activity. Thus a sensitive, specific and non-invasive test is required to identify individuals at risk of developing

CFLD prior to the Y27632 advent of complications. Distinct circulating microRNA (miR) profiles have been identified in various adult chronic liver diseases. In this study we sought to quantify the expression of serum miRs in CFLD patients, CF patients without LD (CFnoLD) and non-CF pediatric controls. Methods: Serum was obtained with informed consent from 102 children (52 CFLD, 30 CFnoLD, 20 non-CF controls). RNA was extracted from 200 μL serum and subjected to Qiagen Human Serum miRNA Real-Time RT-PCR

Array, containing 84 miRs detectable in human serum. Identified candidate miRs (miR-122, miR-25 and miR-21) were validated by real-time RT-PCR using the Exiqon miRCURY LNA PCR system for biofluids. miR expression was normalised to miR-19b and

miR-93, determined by geNorm to be the most stable reference miRs in the array. Results: miR-122 was significantly upregulated in CFLD vs. both CFnoLD and Controls (KW ANOVA, P < 0.0001). Of interest, both miR-25 (KW ANOVA, P = 0.01) and miR-21 (KW ANOVA, P = 0.05) were significantly increased in CFnoLD vs. both CFLD and Controls. Using receiver-operator characteristic check details (ROC) curve analysis, liver disease in CF (i.e. CFLD vs. CFnoLD alone) was discriminated by both miR-122 (AUROC = 0.71, P = 0.002) and miR-25 (AUROC = 0.65, P = 0.026). However, combined logistic regression including all three miRs (−122, −25, −21) showed a highly significant result for the detection of liver disease in CF (AUROC = 0.78, P < 0.0001). Conclusions: This work provides the first evidence of changes to circulating miR levels in CFLD. We demonstrate the potential of miR-122, miR-25 and miR-21 as biomarkers for the early diagnosis of CFLD, perhaps in association with previously discovered discriminatory fibrosis biomarkers. The potential contribution of miRs in predicting disease severity and in the mechanisms of liver pathology in CF patients requires further evaluation.